These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29246616)

  • 1. NEDA treatment target? No evident disease activity as an actionable outcome in practice.
    Parks NE; Flanagan EP; Lucchinetti CF; Wingerchuk DM
    J Neurol Sci; 2017 Dec; 383():31-34. PubMed ID: 29246616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
    Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
    Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Giovannoni G; Tomic D; Bright JR; Havrdová E
    Mult Scler; 2017 Aug; 23(9):1179-1187. PubMed ID: 28381105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
    Giovannoni G; Turner B; Gnanapavan S; Offiah C; Schmierer K; Marta M
    Mult Scler Relat Disord; 2015 Jul; 4(4):329-33. PubMed ID: 26195051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
    Hegen H; Bsteh G; Berger T
    Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
    Mayssam EN; Eid C; Khoury SJ; Hannoun S
    Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
    Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
    Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.
    Smith AL; Cohen JA; Hua LH
    Neurotherapeutics; 2017 Oct; 14(4):952-960. PubMed ID: 28653282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
    Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Sormani MP; Muraro PA; Saccardi R; Mancardi G
    Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
    Guevara C; Garrido C; Martinez M; Farias GA; Orellana P; Soruco W; Alarcón P; Diaz V; Silva C; Kempton MJ; Barker G; de Grazia J
    Front Neurol; 2019; 10():788. PubMed ID: 31396148
    [No Abstract]   [Full Text] [Related]  

  • 14. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term effects of corticosteroids in multiple sclerosis in terms of the "no evidence of disease activity" (NEDA) domains.
    Saied A; Elsaid N; Azab A
    Steroids; 2019 Sep; 149():108401. PubMed ID: 31100292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
    Damasceno A; Damasceno BP; Cendes F
    Mult Scler; 2016 Jan; 22(1):64-72. PubMed ID: 26432855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence of disease activity in multiple sclerosis patients.
    Matta AP; Nascimento OJ; Ferreira AC; Magalhães TN; Benevides TP; Kirmse A; Dib JG; Cal H; Orsini M; Araujo LM
    Expert Rev Neurother; 2016 Nov; 16(11):1279-1284. PubMed ID: 27352830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
    Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
    J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.